Author(s): Kolte BL, Raut BB, Deo AA, Bagool MA, Shinde DB
Abstract Share this page
Abstract A robust, accurate and sensitive high-performance liquid chromatographic method for the determination of rosiglitazone (I) in human plasma has been developed. Pioglitazone (II) was used as internal standard. Both I and II are extracted from plasma using a liquid-liquid extraction procedure. Isocratic separation of I and II is carried out using a reversed-phase Zorbax SB C(18), 15-cm column with mobile phase consisting of methanol and a mixed phosphate buffer (10 mM monobasic sodium phosphate and dibasic sodium phosphate, pH adjusted to 2.6 with ortho-phosphoric acid) in the ratio 30:70 (v/v) and quantified by UV detection at 245 nm. Linearity was established over the range 5-1250 ng/ml using 1 ml human plasma. The method is specific, the endogenous components in plasma do not interfere with I and II. C.V. (\%) of intra-day samples is less than 5.0\% at four concentrations tested namely 5, 10, 500 and 1000 ng/ml. Similarly, over the same nominal concentrations, the precision of inter-day (5 days) samples also results in C.V. (\%) less than 5.0\%. The recoveries of I and II from human plasma were about 79 and 60\%, respectively. This method can be used for routine clinical monitoring of I.
This article was published in J Chromatogr B Analyt Technol Biomed Life Sci
and referenced in Journal of Diabetes & Metabolism